Global Drug Repositioning Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Drug Repositioning market size will reach 31,136 Million USD in 2025 and is projected to reach 44,636 Million USD by 2032, with a CAGR of 5.28% (2025-2032). Notably, the China Drug Repositioning market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Drug repositioning, also known as drug repurposing, is the process of identifying new therapeutic uses for existing drugs that were originally developed for different purposes. Rather than starting from scratch to discover and develop a new drug, drug repositioning involves investigating the potential benefits of established drugs in treating different diseases or conditions. This approach leverages existing safety and efficacy data, expediting the development timeline and potentially reducing costs. Drug repositioning involves a combination of computational analyses, laboratory experiments, and clinical studies to explore the potential of existing compounds in addressing unmet medical needs or expanding their applications beyond their initial intended uses. This strategy has gained prominence as a promising way to bring new treatments to patients more efficiently and with a higher probability of success.
The major global suppliers of Drug Repositioning include Teva, Novartis, Mylan, Johnson & Johnson, Pfizer, Bausch Health, GSK, Glenmark, ChemRar Group, Fujifilm, Dr. Reddy, R-Pharma, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Drug Repositioning. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Drug Repositioning market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Drug Repositioning market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Drug Repositioning industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Drug Repositioning Include:
Teva
Novartis
Mylan
Johnson & Johnson
Pfizer
Bausch Health
GSK
Glenmark
ChemRar Group
Fujifilm
Dr. Reddy
R-Pharma
Drug Repositioning Product Segment Include:
Generic Drugs
Clinical Trial Failed Drugs
Drug Repositioning Product Application Include:
Cardiovascular Diseases
Mental Illness
Cancer
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Drug Repositioning Industry PESTEL Analysis
Chapter 3: Global Drug Repositioning Industry Porter's Five Forces Analysis
Chapter 4: Global Drug Repositioning Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Drug Repositioning Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Drug Repositioning Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Drug Repositioning Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Drug Repositioning market size will reach 31,136 Million USD in 2025 and is projected to reach 44,636 Million USD by 2032, with a CAGR of 5.28% (2025-2032). Notably, the China Drug Repositioning market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Drug repositioning, also known as drug repurposing, is the process of identifying new therapeutic uses for existing drugs that were originally developed for different purposes. Rather than starting from scratch to discover and develop a new drug, drug repositioning involves investigating the potential benefits of established drugs in treating different diseases or conditions. This approach leverages existing safety and efficacy data, expediting the development timeline and potentially reducing costs. Drug repositioning involves a combination of computational analyses, laboratory experiments, and clinical studies to explore the potential of existing compounds in addressing unmet medical needs or expanding their applications beyond their initial intended uses. This strategy has gained prominence as a promising way to bring new treatments to patients more efficiently and with a higher probability of success.
The major global suppliers of Drug Repositioning include Teva, Novartis, Mylan, Johnson & Johnson, Pfizer, Bausch Health, GSK, Glenmark, ChemRar Group, Fujifilm, Dr. Reddy, R-Pharma, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Drug Repositioning. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Drug Repositioning market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Drug Repositioning market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Drug Repositioning industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Drug Repositioning Include:
Teva
Novartis
Mylan
Johnson & Johnson
Pfizer
Bausch Health
GSK
Glenmark
ChemRar Group
Fujifilm
Dr. Reddy
R-Pharma
Drug Repositioning Product Segment Include:
Generic Drugs
Clinical Trial Failed Drugs
Drug Repositioning Product Application Include:
Cardiovascular Diseases
Mental Illness
Cancer
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Drug Repositioning Industry PESTEL Analysis
Chapter 3: Global Drug Repositioning Industry Porter's Five Forces Analysis
Chapter 4: Global Drug Repositioning Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Drug Repositioning Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Drug Repositioning Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Drug Repositioning Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Drug Repositioning Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Drug Repositioning Product by Type
- 1.2.1 Generic Drugs
- 1.2.2 Clinical Trial Failed Drugs
- 1.3 Drug Repositioning Product by Application
- 1.3.1 Cardiovascular Diseases
- 1.3.2 Mental Illness
- 1.3.3 Cancer
- 1.3.4 Others
- 1.4 Global Drug Repositioning Market Size Analysis (2020-2032)
- 1.5 Drug Repositioning Market Development Status and Trends
- 1.5.1 Drug Repositioning Industry Development Status Analysis
- 1.5.2 Drug Repositioning Industry Development Trends Analysis
- 2 Drug Repositioning Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Drug Repositioning Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Drug Repositioning Market Analysis by Country
- 4.1 Global Drug Repositioning Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Drug Repositioning Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Drug Repositioning Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.5 China Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.6 France Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.14 India Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Drug Repositioning Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Drug Repositioning Market Revenue by Key Suppliers (2021-2025)
- 5.2 Drug Repositioning Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Drug Repositioning Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Drug Repositioning Market Analysis by Type
- 6.1 Global Drug Repositioning Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Drug Repositioning Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Teva
- 7.1.1 Teva Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Teva Drug Repositioning Product Portfolio
- 7.1.3 Teva Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Novartis
- 7.2.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Novartis Drug Repositioning Product Portfolio
- 7.2.3 Novartis Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Mylan
- 7.3.1 Mylan Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Mylan Drug Repositioning Product Portfolio
- 7.3.3 Mylan Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Johnson & Johnson
- 7.4.1 Johnson & Johnson Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Johnson & Johnson Drug Repositioning Product Portfolio
- 7.4.3 Johnson & Johnson Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Pfizer
- 7.5.1 Pfizer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Pfizer Drug Repositioning Product Portfolio
- 7.5.3 Pfizer Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 Bausch Health
- 7.6.1 Bausch Health Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Bausch Health Drug Repositioning Product Portfolio
- 7.6.3 Bausch Health Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 GSK
- 7.7.1 GSK Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 GSK Drug Repositioning Product Portfolio
- 7.7.3 GSK Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Glenmark
- 7.8.1 Glenmark Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Glenmark Drug Repositioning Product Portfolio
- 7.8.3 Glenmark Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 ChemRar Group
- 7.9.1 ChemRar Group Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 ChemRar Group Drug Repositioning Product Portfolio
- 7.9.3 ChemRar Group Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Fujifilm
- 7.10.1 Fujifilm Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Fujifilm Drug Repositioning Product Portfolio
- 7.10.3 Fujifilm Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.11 Dr. Reddy
- 7.11.1 Dr. Reddy Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 Dr. Reddy Drug Repositioning Product Portfolio
- 7.11.3 Dr. Reddy Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.12 R-Pharma
- 7.12.1 R-Pharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.12.2 R-Pharma Drug Repositioning Product Portfolio
- 7.12.3 R-Pharma Drug Repositioning Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Drug Repositioning Industry Chain Analysis
- 8.2 Drug Repositioning Product Downstream Application Analysis
- 8.2.1 Global Drug Repositioning Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global Drug Repositioning Revenue and Forecast by Application (2020-2032)
- 8.3 Drug Repositioning Typical Downstream Customers
- 8.4 Drug Repositioning Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
